Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in 1L HER2-overexpressing Non-squamous NSCLC
NCT06899126Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Apr 2030
- Countries
- 24
01
Overview
Phase 3, randomised, open-label trial of trastuzumab deruxtecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Progression Free Survival at 54 months. Started Oct 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06899126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06899126.